Evaluating the impact of glucokinase activation on risk of cardiovascular disease: a Mendelian randomisation analysis

BACKGROUND: Glucokinase activators (GKAs) are an emerging class of glucose lowering drugs that activate the glucose-sensing enzyme glucokinase (GK). Pending formal cardiovascular outcome trials, we applied two-sample Mendelian randomisation (MR) to investigate the impact of GK activation on risk of...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ke, Shi, Mai, Huang, Chuiguo, Fan, Baoqi, Luk, Andrea O. Y., Kong, Alice P. S., Ma, Ronald C. W., Chan, Juliana C. N., Chow, Elaine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503210/
https://www.ncbi.nlm.nih.gov/pubmed/36151532
http://dx.doi.org/10.1186/s12933-022-01613-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503210/
https://www.ncbi.nlm.nih.gov/pubmed/36151532
http://dx.doi.org/10.1186/s12933-022-01613-6

Ejemplares similares